Moderna, Inc. (MRNA)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Moderna, Inc. (MRNA)
Go deeper and ask any question about MRNA
Company Performance
Current Price
as of Sep 13, 2024$68.28
P/E Ratio
N/A
Market Cap
$26.25B
Description
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerMRNA
- Price$68.28-2.01%
Trading Information
- Market Cap$26.25B
- Float89.17%
- Average Daily Volume (1m)5,217,295
- Average Daily Volume (3m)4,312,248
- EPS-$15.36
Company
- Revenue$5.04B
- Rev Growth (1yr)-29.94%
- Net Income-$1.28B
- Gross Margin35.27%
- EBITDA Margin-548.55%
- EBITDA-$1.32B
- EV$38.38B
- EV/Revenue7.61
- P/EN/A
- P/S5.20
Documents
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia